Press Releases :: BiomX, Inc. (PHGE)

Apr 01, 2025 6:30am EDT

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025 6:30am EDT

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025 6:30am EDT

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025 12:35pm EDT

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Feb 26, 2025 8:00am EST

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

Dec 16, 2024 8:00am EST

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

Nov 14, 2024 6:30am EST

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024 12:20pm EST

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024 7:00am EDT

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024 8:00am EDT

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

1
2
3
4
5
6
7
8
9
10
…13
Next

Investor Contact Information

Company

BiomX, Inc.
708 Quince Orchard Rd
Suite 205
Gaithersburg, MD 20878
USA
info@biomx.com

Investor Relations

Ben Cohen
benc@biomx.com